158 related articles for article (PubMed ID: 24291818)
1. Molecular insights on TNKS1/TNKS2 and inhibitor-IWR1 interactions.
Kirubakaran P; Kothandan G; Cho SJ; Muthusamy K
Mol Biosyst; 2014 Feb; 10(2):281-93. PubMed ID: 24291818
[TBL] [Abstract][Full Text] [Related]
2. The binding mechanism of a novel nicotinamide isostere inhibiting with TNKSs: a molecular dynamic simulation and binding free energy calculation.
Feng TT; Zhang YJ; Chen H; Fan S; Han JG
J Biomol Struct Dyn; 2016; 34(3):517-28. PubMed ID: 25933061
[TBL] [Abstract][Full Text] [Related]
3. Evidence for tankyrases as antineoplastic targets in lung cancer.
Busch AM; Johnson KC; Stan RV; Sanglikar A; Ahmed Y; Dmitrovsky E; Freemantle SJ
BMC Cancer; 2013 Apr; 13():211. PubMed ID: 23621985
[TBL] [Abstract][Full Text] [Related]
4.
Loganathan L; Muthusamy K; Jayaraj JM; Kajamaideen A; Balthasar JJ
J Biomol Struct Dyn; 2019 Sep; 37(14):3637-3648. PubMed ID: 30204055
[TBL] [Abstract][Full Text] [Related]
5. Insights of tankyrases: A novel target for drug discovery.
Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
[TBL] [Abstract][Full Text] [Related]
6. Discovery of new dual binding TNKS inhibitors of Wnt signaling inhibition by pharmacophore modeling, molecular docking and bioassay.
Pu Y; Zhang S; Chang Z; Zhang Y; Wang D; Zhang L; Li Y; Zuo Z
Mol Biosyst; 2017 Jan; 13(2):363-370. PubMed ID: 27995250
[TBL] [Abstract][Full Text] [Related]
7. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
[TBL] [Abstract][Full Text] [Related]
8. Novel binding mode of a potent and selective tankyrase inhibitor.
Gunaydin H; Gu Y; Huang X
PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990
[TBL] [Abstract][Full Text] [Related]
9. New molecular insights for 4
Mehta CC; Rohit S; Patel S; Bhatt HG
J Biomol Struct Dyn; 2023; 41(22):13496-13508. PubMed ID: 36755438
[TBL] [Abstract][Full Text] [Related]
10. Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.
Qiu W; Lam R; Voytyuk O; Romanov V; Gordon R; Gebremeskel S; Vodsedalek J; Thompson C; Beletskaya I; Battaile KP; Pai EF; Rottapel R; Chirgadze NY
Acta Crystallogr D Biol Crystallogr; 2014 Oct; 70(Pt 10):2740-53. PubMed ID: 25286857
[TBL] [Abstract][Full Text] [Related]
11. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
[TBL] [Abstract][Full Text] [Related]
12.
Liu J; Feng K; Ren Y
J Biomol Struct Dyn; 2019 Sep; 37(14):3803-3821. PubMed ID: 30261821
[TBL] [Abstract][Full Text] [Related]
13. 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.
Nkizinkiko Y; Desantis J; Koivunen J; Haikarainen T; Murthy S; Sancineto L; Massari S; Ianni F; Obaji E; Loza MI; Pihlajaniemi T; Brea J; Tabarrini O; Lehtiö L
Sci Rep; 2018 Jan; 8(1):1680. PubMed ID: 29374194
[TBL] [Abstract][Full Text] [Related]
14. Tankyrase Sterile α Motif Domain Polymerization Is Required for Its Role in Wnt Signaling.
Riccio AA; McCauley M; Langelier MF; Pascal JM
Structure; 2016 Sep; 24(9):1573-81. PubMed ID: 27499439
[TBL] [Abstract][Full Text] [Related]
15. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.
Wahlberg E; Karlberg T; Kouznetsova E; Markova N; Macchiarulo A; Thorsell AG; Pol E; Frostell Å; Ekblad T; Öncü D; Kull B; Robertson GM; Pellicciari R; Schüler H; Weigelt J
Nat Biotechnol; 2012 Feb; 30(3):283-8. PubMed ID: 22343925
[TBL] [Abstract][Full Text] [Related]
16. Sighting of tankyrase inhibitors by structure- and ligand-based screening and in vitro approach.
Kirubakaran P; Arunkumar P; Premkumar K; Muthusamy K
Mol Biosyst; 2014 Oct; 10(10):2699-712. PubMed ID: 25091558
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into SAM domain-mediated tankyrase oligomerization.
DaRosa PA; Ovchinnikov S; Xu W; Klevit RE
Protein Sci; 2016 Sep; 25(9):1744-52. PubMed ID: 27328430
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Epstein-Barr virus OriP function by tankyrase, a telomere-associated poly-ADP ribose polymerase that binds and modifies EBNA1.
Deng Z; Atanasiu C; Zhao K; Marmorstein R; Sbodio JI; Chi NW; Lieberman PM
J Virol; 2005 Apr; 79(8):4640-50. PubMed ID: 15795250
[TBL] [Abstract][Full Text] [Related]
19. The zinc-binding motif in tankyrases is required for the structural integrity of the catalytic ADP-ribosyltransferase domain.
Sowa ST; Lehtiö L
Open Biol; 2022 Mar; 12(3):210365. PubMed ID: 35317661
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the structure-based rational design of TNKSIs.
Zhan P; Song Y; Itoh Y; Suzuki T; Liu X
Mol Biosyst; 2014 Nov; 10(11):2783-99. PubMed ID: 25211064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]